1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hyperphosphatemia - Overview
- Hyperphosphatemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperphosphatemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperphosphatemia - Companies Involved in Therapeutics Development
- Ardelyx Inc
- China Nuokang Bio-Pharmaceutical Inc
- Chugai Pharmaceutical Co Ltd
- Citragen Pharmaceuticals Inc
- J-Pharma Co Ltd
- OPKO Health Inc
- Panion & Bf Biotech Inc
- Shield Therapeutics Plc
- Unicycive Therapeutics Inc
- Vidasym Inc
- Hyperphosphatemia - Drug Profiles
- CGN-002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- colestilan chloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EOS-789 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fermagate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ferric citrate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- JPH-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lanthanum polystyrene sulfonate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PT-20 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule for Hyperphosphatemia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tenapanor hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- UNI-494 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VS-501 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Hyperphosphatemia - Dormant Projects
- Hyperphosphatemia - Discontinued Products
- Hyperphosphatemia - Product Development Milestones
- Featured News & Press Releases
- Jun 15, 2020: Ardelyx announces positive second data analysis from ongoing NORMALIZE phase 4 study evaluating Tenapanor in CKD patients on dialysis
- Dec 04, 2019: Ardelyx reports positive data from tenapanor’s Phase III CKD trial
- Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019
- Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication
- Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment
- Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
- Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tenapanor for Hyperphosphatemia patients on dialysis in Japan
- Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tenapanor and Sevelamer when dosed in combination for elevated serum phosphorus
- Aug 29, 2018: Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
- May 21, 2018: Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
- Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor
- Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings
- Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
- Jan 06, 2017: Shield Therapeutics Provides Update on PT20
- Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Hyperphosphatemia, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020
- Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020
- Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020
- Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
- Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
- Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020
- Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020
- Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020
- Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020
- Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020
- Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020
- Hyperphosphatemia - Dormant Projects, H1 2020
- Hyperphosphatemia - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Hyperphosphatemia, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Ardelyx Inc
- China Nuokang Bio-Pharmaceutical Inc
- Chugai Pharmaceutical Co Ltd
- Citragen Pharmaceuticals Inc
- J-Pharma Co Ltd
- OPKO Health Inc
- Panion & Bf Biotech Inc
- Shield Therapeutics Plc
- Unicycive Therapeutics Inc
- Vidasym Inc
